These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35146577)

  • 21. Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma.
    Allison C
    Issues Emerg Health Technol; 2007 Sep; (102):1-6. PubMed ID: 17824141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.
    Lee EW; Alanis L; Cho SK; Saab S
    Korean J Radiol; 2016; 17(4):472-88. PubMed ID: 27390539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the Adverse Event Profile of TheraSphere
    Kallini JR; Gabr A; Thorlund K; Balijepalli C; Ayres D; Kanters S; Ebrahim S; Mills E; Lewandowski RJ; Salem R
    Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1033-1043. PubMed ID: 28246879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
    Kousik V; Promila P; Verma R; Gupta A
    Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
    Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
    J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calculation of tumour and normal tissue biological effective dose in
    Gallio E; Richetta E; Finessi M; Stasi M; Pellerito RE; Bisi G; Ropolo R
    Phys Med; 2016 Dec; 32(12):1738-1744. PubMed ID: 27876284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes.
    Boas FE; Bodei L; Sofocleous CT
    J Nucl Med; 2017 Sep; 58(Suppl 2):104S-111S. PubMed ID: 28864605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan.
    Chiesa C; Maccauro M; Romito R; Spreafico C; Pellizzari S; Negri A; Sposito C; Morosi C; Civelli E; Lanocita R; Camerini T; Bampo C; Bhoori S; Seregni E; Marchianò A; Mazzaferro V; Bombardieri E
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):168-97. PubMed ID: 21386789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic radioembolization with Yttrium-90 glass microspheres for treatment of primary liver cancer.
    Cao X; He N; Sun J; Tan J; Zhang C; Yang J; Lu T; Li J
    Chin Med J (Engl); 1999 May; 112(5):430-2. PubMed ID: 11593513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
    J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioembolization, Principles and indications.
    Ahmadzadehfar H; Ilhan H; Lam MGEH; Sraieb M; Stegger L
    Nuklearmedizin; 2022 Jun; 61(3):262-272. PubMed ID: 35354218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
    Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
    J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with
    Watanabe M; Grafe H; Theysohn J; Schaarschmidt B; Ludwig J; Jochheim L; Jeschke M; Schmidt H; Fendler WP; Moraitis A; Herrmann K; Pomykala KL; Weber M
    J Nucl Med; 2023 Jul; 64(7):1102-1108. PubMed ID: 37290792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.
    Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N
    Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study.
    Kis B; Shridhar R; Mhaskar R; Gyano M; Frakes JM; El-Haddad G; Choi J; Kim RD; Hoffe SE
    J Vasc Interv Radiol; 2023 Sep; 34(9):1547-1555. PubMed ID: 37210030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating radioembolization ((90)Y microspheres) into current treatment options for liver tumors: introduction to the international working group report.
    Kennedy A; Coldwell D; Sangro B; Wasan H; Salem R
    Am J Clin Oncol; 2012 Feb; 35(1):81-90. PubMed ID: 20938320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
    Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
    Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. State of the art: radiolabeled microspheres treatment for liver malignancies.
    Deleporte A; Flamen P; Hendlisz A
    Expert Opin Pharmacother; 2010 Mar; 11(4):579-86. PubMed ID: 20163269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.